Harnessing evolutionary biology to combat infectious disease by Little, Thomas et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Harnessing evolutionary biology to combat infectious disease
Citation for published version:
Little, T, Allen, JE, Babayan, SA, Matthews, KR & Colegrave, N 2012, 'Harnessing evolutionary biology to
combat infectious disease' Nature Medicine, vol. 18, no. 2, pp. 217-220. DOI: 10.1038/nm.2572
Digital Object Identifier (DOI):
10.1038/nm.2572
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Nature Medicine
Publisher Rights Statement:
Free in PMC.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Harnessing evolutionary biology to combat infectious disease
Tom J. Little1, Judith E. Allen, Simon A. Babayan, Keith R. Matthews, and Nick Colegrave
Centre for Immunity, Infection and Evolution, School of Biological Sciences, University of
Edinburgh, West Mains Road, EH9 3JT Edinburgh, United Kingdom
Abstract
Pathogens exhibit remarkable abilities to flout therapeutic intervention. This outcome is driven by
evolution, either as a direct response to intervention (e.g. the evolution of antibiotic resistance), or
through long-term coevolution generating host or parasite traits that interact with therapy in
undesirable or unpredicted ways. To make progress, the concepts and techniques of evolutionary
biology must be deeply integrated with traditional approaches to immunology and pathogen
biology. An interdisciplinary approach can inform control strategies, or even patient treatment,
positioning us to meet the current and future challenges of controlling infectious diseases.
The last century has seen considerable progress in controlling infectious diseases, but
success is far from universal. Pathogens remain a major health burden, with over 9.8 million
people per year dying from infections (over 16.5% of annual deaths), half of them children1.
Thus, despite intense investment in the development of vaccines and therapeutics in the 20th
century, old (existing and resurgent) and new (emerging) pathogens remain a significant
threat. Some treatments or control efforts begin effectively, and then lose ground. Other
disease problems appear intractable, and control programs fail at an early stage. What causes
failure? What underlies variability in the short and longer-term success of control measures?
A major problem is evolution. And evolution, aside from being pervasive, often works in
complex ways with outcomes that are challenging to predict.
This is the age of biology, but to fully exploit the moment, we need to recognise the scale
and complexity of the problems posed by evolution, and then find a way to productively
integrate evolutionary biology with traditional biomedical research. The fact that these fields
typically approach problems in markedly disparate ways is a challenge that needs to be
overcome if we are to understand, control or even manipulate evolutionary processes to our
benefit.
Evolution: the scale of the problem
The threat posed by evolution is vast and falls into two broad categories. First, intervention
drives evolution. The evolution of bacterial resistance to antibiotics and vector resistance to
pesticides are the classic (and ongoing) examples of intervention-driven evolution2-4, though
many other interventions may provoke undesirable evolution5-8. It is crucial to note that, in
the majority of these cases, resistance did not evolve as expected, and intuition stemming
from an overly simplistic view of the evolutionary process has proven a poor guide to
identifying threats and exploiting new opportunities for control (Box 1).
Second, past evolution confounds intervention. Complex traits that have been fine-tuned by
aeons of natural selection and coevolution can incidentally thwart control efforts. These
include the classic examples of pathogen adaptations: hiding with an non-antigenic cloak9,
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antigen switching10, or directly manipulating the immune system11-15, each of which defies
our efforts to identify targets for vaccination. Evolved traits can also become intervention-
driven threats. For example helminth parasites appear to have the capacity to monitor host
immune status and shift reproduction into high gear, thereby enhancing transmission7. Such
plasticity in reproductive schedules, which the parasite has the capacity for due to a long
evolutionary interaction with immune systems, can also be direct responses to immune
effectors that are boosted by vaccination7. Host adaptations can also confound treatment.
For example, it was thought that anaemia was a pathological consequence of bacterial
infection, but patients died when iron was given because anaemia was actually an adaptation
by the host to remove the iron upon which bacteria rely. The role of iron remains a current
treatment issue for a variety of parasites and pathogens16,17. To get treatment right, we must
understand why an adaptation such as anaemia evolved. A similar reasoning applies to fever.
Should we always treat mild fever during an infection? This depends on whether the fever,
or any pathology, is an evolutionary adaptation, and if so for whom – the host or the
parasite? (Box 1).
Productively integrating evolutionary biology
Creating novel, long-lasting, therapies against historically elusive pathogens (e.g.
Plasmodium, helminths), or sustaining the control initiative against resurgent and new
pathogens (e.g. tuberculosis, influenza, or opportunistic bacteria), will require the integration
of pathogen biology and immunology with evolutionary biology. From the outset,
integration will involve overcoming language barriers-evolutionary biologists and traditional
biomedical researchers often speak very different languages, and we should begin preparing
young scientists to become fluent in diverse terminologies. These disciplines also differ
substantially in their respective approaches. Infectious disease biologists have traditionally
interrogated systems at the molecular and cellular levels, while evolutionary biologists more
often consider whole organism fitness, polymorphism and changes in populations through
time (Figure 1). For instance, immunologists strive to reduce variation (e.g. environmental,
genetic) to elucidate mechanistic pathways, but for ecologists and evolutionary biologists,
variation is the subject, as they analyse changes in fitness in relation to genetic and
environmental heterogeneity. There is room for the biomedical sciences to shift away from a
focus on inbred model organisms in the laboratory to emphasise the responses of real hosts
in the wild18,19. Equally, there is room for evolutionary biology and ecology to strengthen
their appreciation of the mechanistic underpinnings of traits, and transform this knowledge
into predictive models. We may require more study systems, as humans and mice may not
be ideal for evolutionary studies, but the role of traditional model systems could also be
expanded to test whether patterns observed in the laboratory can be generalised to other
environments (e.g. 19,20,21).
We do not expect integration to be easy. Disentangling the complex molecular biology of
host-pathogen interactions is not straightforward, and although the elegant simplicity of
Darwin’s theory of natural selection can tempt us into thinking the evolutionary outcomes
will be easy to predict, they are not (Box 1). Resistance to even a single drug may involve
multiple mechanisms and mutational targets, and predicting the spread of resistance in real
populations will require complex, parameter-rich models where estimating each parameter
will represent a significant challenge. This complexity means we cannot use a cursory
understanding of evolutionary biology to guess at evolutionary outcomes. Technological
transformations, particularly in genomics, bioinformatics and computing power, are already
aiding integration by creating new opportunities to map genotype and molecular mechanism
onto phenotype22 in models and non-models alike. We will require scientists with mastery
of the new technologies, but perhaps the most important skill will be the ability to
contextualise the ever-expanding quantities of data.
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With the right data and outlook, we can begin to ask biomedically relevant questions at
multiple levels, creating a synergy that allows biological insights to be translated into
control strategies. For example, an important question is why hasn’t natural selection purged
susceptible (to infection) genotypes from natural populations? Genetic work has revealed
possible answers by showing that there are evolutionary trade-offs, where parasite-resistant
individuals suffer chronic disease. A recent example, obtained by combining data from
association studies and characterising signatures of natural selection, is a polymorphism in
the human Apo-L1 protein that confers trypanosome resistance, but also kidney disease23.
Sickle-cell anemia and malaria is the entrenched example of such a trade-off, but even this is
being reassessed, as data point to new understanding of why sickle cells are protective. In
particular, rather than reducing parasite load, it is now surmised that sickle cells release
more heme, inducing the production of heme-neutralising systems that assist with both the
sickle cell pathology and cerebral malaria24. This form of protection, where pathology is
reduced without reducing parasite numbers, puts fundamentally different selective pressures
on parasite populations25. Ultimately, analysis of selection and the resulting polymorphism
can generate predictive biomarkers, which assist analyses of disease spread. Whilst
genotyping and phenotyping in the field remain challenging in areas with poor health
infrastructure, as genome sequencing studies continue to analyse more dispersed human
populations, it might be possible to use immune polymorphisms to predict disease
susceptibility and, with understanding of local pathogen diversity, therapies could even be
tailored to specific geographical groups.
In addition to these human studies, multi-generational data sets on wild mammals are now
allowing us to associate immunological data with comprehensive measures of Darwinian
fitness in the context of optimal immunity. For example, the novel application of
immunological tools has shown that highly immune-responsive feral sheep suffer
autoimmunity, which reduces reproductive success but enhances survival due to their lower
parasite burdens26. The balance of the immune system is also influenced by coinfection:
removing one set of pathogens in a co-infection or altering commensal populations can
increase susceptibility to other pathogens27, leading to an imbalanced immune
response28-30, with potential for autoimmunity, allergy and asthma. Hence, pathogen
exposure, and long-term coevolutionary interactions, may not always select striking and
discrete polymorphisms such as those at Apo-L1, and instead may select for complex and
graduated genetic responses (best studied with the tools of quantitative genetics) that respect
the demands of polyparasitism. New pathogen control strategies must address optimal
immunity in the real world, where multiple infections are the norm, to avoid adverse
immune consequences or the emergence of new, or previously rare, pathogens.
Thus, analyses of how pathogens, and pathogen diversity, evolve in response to control
measures are crucial. New approaches are making it possible to rapidly identify medically
relevant features of pathogens and the timescales on which they arise. For example,
population genomic analysis of ongoing epidemics are elucidating the timing of the
emergence of drug resistance, changes in host range and pathogenesis, and identifying
source populations and species likely to seed the next epidemic31-33. The pace at which we
can now sequence genomes is key here, and, ultimately, such phylodynamic approaches may
provide the early-warning signals for disease emergence or drug resistance, allowing us to
help predict, and limit, their spread34-39. Similarly, laboratory selection of parasite resistance
to new drugs, coupled with genome sequencing and other molecular techniques, is proving
useful in identifying the mechanisms of drug action, cross resistance to other drugs and the
potential for control failure in both Mycobacterium tuberculosis40 and Plasmodium41,
amongst other top killers. Biomedical researchers can and should follow up the
identification key traits with mathematical models that can generate predictions for the
impact of control strategies. If we could travel back in time to the beginning of the antibiotic
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era and use evolutionary biology to apply these drugs in a manner less likely to provoke
undesired evolution, we would. The lessons learned through integrative strategies can and
must be applied to future pathogen control because the cost of developing and testing new
therapeutics is so high that any strategy to prolong their efficacy, however slightly, is both
morally and economically compelling.
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Box 1
Threats and Opportunities
Evolutionary outcomes can be challenging to predict. This has generated many
unforeseen dangers, but an appreciation of the evolutionary strategies used by pathogens
can also foster intriguing solutions to therapy and controlling transmission.
• Resistance at a bargain. The ability of microbes to resist antibiotics should
negatively impact their fitness in the absence of treatment, as resistance traits
are likely to be costly. However, mutations that confer resistance are often
quickly followed by additional mutations, elsewhere in the genome, that
compensate the costs of resistance. Compensatory mutations can even increase
the fitness of the resistant genotype above that of the original sensitive
genotype, creating ‘superbugs’ which outcompete other bacteria both in the
presence and absence of antibiotics.
• Old enemies. A standard view has been that long-term host-pathogen
associations inevitably co-evolve to become less harmful. However, parasites
actually face an evolutionary dilemma as reproducing too quickly may kill the
host before transmission takes place, but sometimes there are advantages to
reproducing rapidly (even when this harms the host), such as upon co-infection
with a competitor. These counteracting demands lead to the evolution of an
intermediate level of virulence which maximises parasite transmission2. There
is a clear potential for treatments that reduce virulence without directly harming
pathogens to favour fast-growing parasites5,6.
• Family matters. Many aspects of pathogen biology only make sense in light of
the evolutionary theory of kin selection. For example, some Salmonella bacteria
induce an immune response that effectively empties the host gut of competing
pathogens. However, this immune response will also harm Salmonella, but this
suicide strategy makes sense if it helps nearby kin who share genes with the
original Salmonella strain42.
• Hit ’em late, hit ’em softly. Evolutionary theory has suggested a blueprint for
“evolution proof” insecticides: target old rather than young individuals43,44. At
first sight, this counters the intuition that the best way to control a pest is to hit
them quickly and hard, but an insecticide that kills young mosquitoes maximises
selection for resistance. However, evolutionary biology predicts that an
insecticide that kills later, once most reproduction has occurred, will minimise
selection for resistance, as the strength of natural selection decreases with age.
In parasites where transmission generally occurs from older vectors, e.g.
Plasmodium, there may be an age window that could be targeted when selection
for insecticide resistance is weak and before transmission.
• RAMPs. Ribosomally-synthesised antimicrobial peptides(RAMPs) are part of
the innate immune system of all multicellular organisms, and bacteria do not
appear to have resistance to them, raising hope that these peptides might be used
therapeutically. However, resistance easily evolves45 when RAMPs are studied
under the conditions that evolutionary theory predicts will provoke the evolution
of resistance. Coincidentally, these conditions are similar to the those bacteria
would experience if RAMPs were used therapeutically.
• Deceptive epitopes. Immunodominance is the preference of the immune system
towards a limited set of epitopes. By strategically positioning immunodominant
epitopes, the influenza virus can “lock” the immune system into a relatively
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ineffective and strain-specific response. Thus, evolution suggests that attempting
to mimic the natural immune response may play into the pathogen’s hands.
Instead, vaccine constructs that mask the immunodominant deceptive epitopes
may allow the immune response to be refocused toward less antigenic but more
conserved epitopes, generating more effective, wide ranging immunity46,47.
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Figure 1.
A central aim of all biomedical research is to elucidate mechanisms associated with
infectious disease. Much basic biomedical research, for example immunology or pathogen
biology, has its roots in cellular and molecular biology, and as such, has sought to (1)
identify cellular or molecular mechanisms (e.g. pathogen virulence factors or host immune
deficiencies) that place an individual at risk of contracting or expressing disease. The study
of evolution (2), by contrast, is principally a form of population biology, and in the context
of infectious disease, evolutionary biology seeks to identify mechanisms (prominently,
natural selection) that change whole populations towards either a greater or lower average
risk of infection. There has been substantial progress towards identifying (3) genetic
variation for the cellular/molecular mechanisms that put individuals at greater risk of
disease; evolutionary biology then studies (4) how the frequencies of these genetic variants
may change over time due to natural selection. Thus, genetics (5), either molecular or
quantitative, provides an important link between traditional biomedical science and
evolutionary biology.
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